尤文肉瘤的治疗研究进展
|
摘要
尤文肉瘤是一种高度恶性的肿瘤,其主要治疗方法为局部手术切除、化学治疗、放射治疗。对于局部尤文肉瘤,放射治疗是传统主要疗法;直接手术切除适用于小的局部尤文肉瘤,体积大的中心性尤文肉瘤可选择外科手术和(或)放射治疗;此外,辅助或新辅助化疗也取得了良好疗效。复发、转移或难治性尤文肉瘤的治疗尚未取得突破性进展:转移性尤文肉瘤应对患者的原发灶及转移灶同时进行综合治疗;复发性或难治性尤文肉瘤治疗疗效除患者个体因素外,还取决于复发肿瘤的部位及初始治疗方案。近年来,靶向药物治疗也逐渐应用于尤文肉瘤。整体来说,临床上应根据尤文肉瘤的发病部位、肿瘤分期及肿瘤大小采取适合的个体化治疗策略。本文主要就尤文肉瘤的化学治疗、放射治疗、手术治疗方面的研究进展进行综述。
引文
[1]EWING J.Diffuse endothelioma of bone[J].Proc New York Path,1921,21:17-24.
[2]LI T,ZHANG F,CAO Y,et al.Primary Ewing′s sarcoma/primitive neuroectodermal tumor of the ileum:case report of a 16-year-old Chinese female and literature review[J].Diagn Pathol,2017,12(1):37.
[3]LIAO Y S,CHIANG I H,GAO H W.A mesenteric primary peripheral Ewing′s sarcoma/primitive neuroectodermal tumor with molecular cytogenetic analysis:report of a rare case and review of literature[J].Indian J Pathol Microbiol,2018,61(2):248-251.
[4]KONDO T.Current status of proteomics in Ewing′s sarcoma[J/OL].Proteomics Clin Appl,2018.(2018-07-10)[2018-12-21].https://doi.org/10.1002/prca.201700130.
[5]ALLEGRETTI M,CASINI B,MANDOJ C,et al.Precision diagnostics of Ewing′s sarcoma by liquid biopsy:circulating EWS-FLI1fusion transcripts[J].Ther Adv Med Oncol,2018,10:1758835918774337.
[6]HAYASHI M,CHU D,MEYER C F,et al.Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA[J].Cancer,2016,122(19):3015-3023.
[7]LUDWIG J A.Ewing sarcoma:historical perspectives,current state-of-the-art,and opportunities for targeted therapy in the future[J].Curr Opin Oncol,2008,20(4):412-418.
[8]YOGESH T,SHETTY A,KESWANI H,et al.Aggressive high-grade Ewing′s sarcoma of maxilla:A rare case report[J].J Oral Maxillofac Pathol,2018,22(Suppl 1):S48-53.
[9]GIBBS C P,WEBER K,SCARBOROUGH M T,et al.Malignant bone tumors[J].Instructional course lectures,2001,83(11):1728.
[10]UYETURK U,HELVACI K,DEMIRCI A,et al.Clinical outcomes and prognostic factors of adult′s Ewing sarcoma family of tumors:single center experience[J].Contemp Oncol(Pozn),2016,20(2):141-146.
[11]NAZEER A,KANDIL A,ZAHRA O,et al.Clinicopathological features and treatment outcomes in Ewing′s sarcoma patients:a 10-year experience of Alexandria clinical oncology department[J].Indian J Med Paediatr Oncol,2017,38(3):316-320.
[12]RODRGUEZ-GALINDO C,NAVID F,LIU T,et al.Prognostic factors for local and distant control in Ewing sarcoma family of tumors[J].Ann Oncol,2008,19(4):814-820.
[13]GREVENER K,HAVEMAN L M,RANFT A,et al.Management and outcome of Ewing sarcoma of the head and neck[J].Pediatr Blood Cancer,2016,63(4):604-610.
[14]ARSHI A,SHARIM J,PARK D Y,et al.Prognostic determinants and treatment outcomes analysis of osteosarcoma and Ewing sarcoma of the spine[J].Spine J,2017,17(5):645-655.
[15]DAVENPORT J R,VO K T,GOLDSBY R,et al.Conditional survival and Predictors of late Death in patients with Ewing sarcoma[J].Pediatr Blood Cancer,2016,63(6):1091-1095.
[16]DRAMIS A,GRIMER R J,MALIZOS K,et al.Non-Metastatic Pelvic Ewing′s Sarcoma:oncologic outcomes and evaluation of prognostic factors[J].Acta Orthop Belg,2016,82(2):216-221.
[17]TENNETI P,ZAHID U,IFTIKHAR A,et al.Role of high-dose chemotherapy and autologous hematopoietic cell transplantation for children and young adults with relapsed Ewing′s sarcoma:a systematic review[J].Sarcoma,2018(2018):2640674.
[18]JAHNUKAINEN K,KALLIO P,KOIVUSALO A,et al.High-dose thiotepa as consolidation therapy with autologous hematopoietic stem cell transplantation for high-risk Ewing family tumors:single-institution experience[J].JPediatr Hematol Oncol,2015,37(7):536-542.
[19]ALCINDOR T.Response of refractory Ewing sarcoma to pazopanib[J].Acta Oncol,2015,54(7):1063-1064.
[20]SHEFFIELD N C,PIERRON G,KLUGHAMMER J,et al.DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma[J].Nat Med,2017,23(3):386-395.
[21]WILKY B A,KIM C,MCCARTY G,et al.RNA helicase DDX3:a novel therapeutic target in Ewing sarcoma[J].Oncogene,2016,35(20):2574-2583.
[22]DUBOIS S G,KRAILO M D,GEBHARDT M C,et al.Comparative evaluation of local control strategies in localized Ewing sarcoma of bone:a report from the Children′s Oncology Group[J].Cancer,2015,121(3):467-475.
[23]CANTER R J.Chemotherapy:does neoadjuvant or adjuvant therapy improve outcomes?[J].Surg Oncol Clin NAm,2016,25(4):861-872.
[24]GRIER H E,KRAILO M D,TARBELL N J,et al.Addition of ifosfamide and etoposide to standard chemotherapy for Ewing′s sarcoma and primitive neuroectodermal tumor of bone[J].N Engl J Med,2003,348(8):694-701.
[25]OBATA H,UEDA T,KAWAI A,et al.Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan[J].Cancer,2007,109(4):767-775.
[26]MISER J S,KRAILO M D,TARBELL N J,et al.Treatment of metastatic Ewing′s sarcoma or primitive neuroectodermal tumor of bone:evaluation of combination ifosfamide and etoposide-a Children′s Cancer Group and Pediatric Oncology Group study[J].J Clin Oncol,2004,22(14):2873-2876.
[27]WOMER R B,WEST D C,KRAILO M D,et al.Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma:a report from the Children′s Oncology Group[J].J Clin Oncol,2012,30(33):4148-4154.
[28]DONALDSON S S.Ewing sarcoma:radiation dose and target volume[J].Pediatr Blood Cancer,2004,42(5):471-476.
[29]DUNST J,HOFFMANN C,AHRENS S,et al.Surgery versus radiotherapy in Ewing′s sarcoma with good prognosis.Analysis of the CESS-86 data[J].Strahlenther Onkol,1996,172(5):244-249.
[30]BOLEK T W,MARCUS R B Jr,MENDENHALL N P,et al.Local control and functional results after twice-daily radiotherapy for Ewing′s sarcoma of the extremities[J].Int J Radiat Oncol Biol Phys,1996,35(4):687-692.
[31]TALLEUR A C,NAVID F,SPUNT S L,et al.Limited margin radiation therapy for children and young adults with Ewing sarcoma achieves high rates of local tumor control[J].Int J Radiat Oncol Biol Phys,2016,96(1):119-126.
[32]ALBERGO J,GASTON C L L,PARRY M C,et al.Risk analysis factors for local recurrence in Ewing′s sarcoma:when should adjuvant radiotherapy be administered?[J].Bone Joint J,2018,100(2):247-255.
[33]GHAREDAGHI M,PEIVANDI M T,MAZLOOMI M,et al.Evaluation of clinical results and complications of structural allograft reconstruction after bone tumor surgery[J].Arch Bone Jt Surg,2016,4(3):236-242.
[34]OZAKI T,HILLMANN A,HOFFMANN C,et al.Significance of surgical margin on the prognosis of patients with Ewing′s sarcoma:a report from the Cooperative E-wing′s Sarcoma Study[J].Cancer,1996,78(4):892-900.
[35]SLUGA M,WINDHAGER R,LANG S,et al.The role of surgery and resection margins in the treatment of Ewing′s sarcoma[J].Clin Orthop Relat Res,2001(392):394-399.
[36]MIZOSHIRI N,SHIRAI T,TERAUCHI R,et al.Limb saving surgery for Ewing′s sarcoma of the distal tibia:a case report[J].BMC Cancer,2018,18(1):503.
[37]EL-NEGERY A,ELMOGHAZY N A,ABD-ELLATIFM S,et al.Vascularized fibular medialization for reconstruction of the tibial defects following tumour excision[J].Int Orthop,2017,41(10):2179-2187.
[38]RENARD A J,VETH R P,SCHREUDER H W,et al.Function and complications after ablative and limbsalvage therapy in lower extremity sarcoma of bone[J].JSurg Oncol,2000,73(4):198-205.
[39]CHOI Y,LIM D H,LEE S H,et al.Role of radiotherapy in the multimodal treatment of Ewing sarcoma family tumors[J].Cancer Res Treat,2015,47(4):904-912.
[40]MILLER B J,GAO Y,DUCHMAN K R.Does surgery or radiation provide the best overall survival in Ewing′s sarcoma?A review of the National Cancer Data Base[J].JSurg Oncol,2017,116(3):384-390.
[41]FOULON S,BRENNAN B,GASPAR N,et al.Can postoperative radiotherapy be omitted in localised standardrisk Ewing sarcoma?An observational study of the EuroEWING group[J].Eur J Cancer,2016,61:128-136.
[42]AHMED S K,ROBINSON S I,ARNDT C A S,et al.Pelvis Ewing sarcoma:local control and survival in the modern era[J].Pediatr Blood Cancer,2017,64(9):e26504.
[43]PURI A,GULIA A,CRASTO S,et al.Does radiotherapy after surgery affect outcomes in Ewing′s sarcoma of the pelvis?[J].Indian J Orthop,2018,52(1):73-76.
[44]BISWAS B,RASTOGI S,KHAN S A,et al.Outcomes and prognostic factors for Ewing-family tumors of the extremities[J].J Bone Joint Surg Am,2014,96(10):841-849.
[45]PAULINO A C,MAI W Y,TEH B S.Radiotherapy in metastatic Ewing sarcoma[J].Am J Clin Oncol,2013,36(3):283-286.
[46]ESIASHVILI N,GOODMAN M,MARCUS R B Jr.Changes in incidence and survival of Ewing sarcoma patients over the past 3decades:Surveillance epidemiology and end results data[J].J Pediatr Hematol Oncol,2008,30(6):425-430.
[47]RODRIGUEZ-GALINDO C,BILLUPS C A,KUN L E,et al.Survival after recurrence of Ewing tumors[J].Cancer,2002,94(2):561-569.
[48]BACCI G,FERRARI S,LONGHI A,et al.Role of surgery in local treatment of Ewing′s sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy[J].Oncol Rep,2004,11(1):111-120.
[49]ROBINSON S I,AHMED S K,OKUNO S H,et al.Clinical outcomes of adult patients with relapsed Ewing sarcoma:a 30-year single-institution experience[J].Am J Clin Oncol,2014,37(6):585-591.
[50]MCTIERNAN A,DRIVER D,MICHELAGNOLI M P,et al.High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing′s sarcoma family of tumours[J].Ann Oncol,2006,17(8):1301-1305.
[51]FERRARI S,DEL PREVER A B,PALMERINI E,et al.Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma[J].Pediatr Blood Cancer,2009,52(5):581-584.
[52]RACIBORSKA A,BILSKA K,DRABKO K,et al.Vincristine,irinotecan,and temozolomide in patients with relapsed and refractory Ewing sarcoma[J].Pediatr Blood Cancer,2013,60(10):1621-1625.
[53]YOON J H,KWON M M,PARK H J,et al.A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors[J].BMC Cancer,2014,14:622.
[54]LI S,YANG Q,WANG H,et al.Prognostic significance of serum lactate dehydrogenase levels in Ewing′s sarcoma:a meta-analysis[J].Mol Clin Oncol,2016,5(6):832-838.
[2]LI T,ZHANG F,CAO Y,et al.Primary Ewing′s sarcoma/primitive neuroectodermal tumor of the ileum:case report of a 16-year-old Chinese female and literature review[J].Diagn Pathol,2017,12(1):37.
[3]LIAO Y S,CHIANG I H,GAO H W.A mesenteric primary peripheral Ewing′s sarcoma/primitive neuroectodermal tumor with molecular cytogenetic analysis:report of a rare case and review of literature[J].Indian J Pathol Microbiol,2018,61(2):248-251.
[4]KONDO T.Current status of proteomics in Ewing′s sarcoma[J/OL].Proteomics Clin Appl,2018.(2018-07-10)[2018-12-21].https://doi.org/10.1002/prca.201700130.
[5]ALLEGRETTI M,CASINI B,MANDOJ C,et al.Precision diagnostics of Ewing′s sarcoma by liquid biopsy:circulating EWS-FLI1fusion transcripts[J].Ther Adv Med Oncol,2018,10:1758835918774337.
[6]HAYASHI M,CHU D,MEYER C F,et al.Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA[J].Cancer,2016,122(19):3015-3023.
[7]LUDWIG J A.Ewing sarcoma:historical perspectives,current state-of-the-art,and opportunities for targeted therapy in the future[J].Curr Opin Oncol,2008,20(4):412-418.
[8]YOGESH T,SHETTY A,KESWANI H,et al.Aggressive high-grade Ewing′s sarcoma of maxilla:A rare case report[J].J Oral Maxillofac Pathol,2018,22(Suppl 1):S48-53.
[9]GIBBS C P,WEBER K,SCARBOROUGH M T,et al.Malignant bone tumors[J].Instructional course lectures,2001,83(11):1728.
[10]UYETURK U,HELVACI K,DEMIRCI A,et al.Clinical outcomes and prognostic factors of adult′s Ewing sarcoma family of tumors:single center experience[J].Contemp Oncol(Pozn),2016,20(2):141-146.
[11]NAZEER A,KANDIL A,ZAHRA O,et al.Clinicopathological features and treatment outcomes in Ewing′s sarcoma patients:a 10-year experience of Alexandria clinical oncology department[J].Indian J Med Paediatr Oncol,2017,38(3):316-320.
[12]RODRGUEZ-GALINDO C,NAVID F,LIU T,et al.Prognostic factors for local and distant control in Ewing sarcoma family of tumors[J].Ann Oncol,2008,19(4):814-820.
[13]GREVENER K,HAVEMAN L M,RANFT A,et al.Management and outcome of Ewing sarcoma of the head and neck[J].Pediatr Blood Cancer,2016,63(4):604-610.
[14]ARSHI A,SHARIM J,PARK D Y,et al.Prognostic determinants and treatment outcomes analysis of osteosarcoma and Ewing sarcoma of the spine[J].Spine J,2017,17(5):645-655.
[15]DAVENPORT J R,VO K T,GOLDSBY R,et al.Conditional survival and Predictors of late Death in patients with Ewing sarcoma[J].Pediatr Blood Cancer,2016,63(6):1091-1095.
[16]DRAMIS A,GRIMER R J,MALIZOS K,et al.Non-Metastatic Pelvic Ewing′s Sarcoma:oncologic outcomes and evaluation of prognostic factors[J].Acta Orthop Belg,2016,82(2):216-221.
[17]TENNETI P,ZAHID U,IFTIKHAR A,et al.Role of high-dose chemotherapy and autologous hematopoietic cell transplantation for children and young adults with relapsed Ewing′s sarcoma:a systematic review[J].Sarcoma,2018(2018):2640674.
[18]JAHNUKAINEN K,KALLIO P,KOIVUSALO A,et al.High-dose thiotepa as consolidation therapy with autologous hematopoietic stem cell transplantation for high-risk Ewing family tumors:single-institution experience[J].JPediatr Hematol Oncol,2015,37(7):536-542.
[19]ALCINDOR T.Response of refractory Ewing sarcoma to pazopanib[J].Acta Oncol,2015,54(7):1063-1064.
[20]SHEFFIELD N C,PIERRON G,KLUGHAMMER J,et al.DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma[J].Nat Med,2017,23(3):386-395.
[21]WILKY B A,KIM C,MCCARTY G,et al.RNA helicase DDX3:a novel therapeutic target in Ewing sarcoma[J].Oncogene,2016,35(20):2574-2583.
[22]DUBOIS S G,KRAILO M D,GEBHARDT M C,et al.Comparative evaluation of local control strategies in localized Ewing sarcoma of bone:a report from the Children′s Oncology Group[J].Cancer,2015,121(3):467-475.
[23]CANTER R J.Chemotherapy:does neoadjuvant or adjuvant therapy improve outcomes?[J].Surg Oncol Clin NAm,2016,25(4):861-872.
[24]GRIER H E,KRAILO M D,TARBELL N J,et al.Addition of ifosfamide and etoposide to standard chemotherapy for Ewing′s sarcoma and primitive neuroectodermal tumor of bone[J].N Engl J Med,2003,348(8):694-701.
[25]OBATA H,UEDA T,KAWAI A,et al.Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan[J].Cancer,2007,109(4):767-775.
[26]MISER J S,KRAILO M D,TARBELL N J,et al.Treatment of metastatic Ewing′s sarcoma or primitive neuroectodermal tumor of bone:evaluation of combination ifosfamide and etoposide-a Children′s Cancer Group and Pediatric Oncology Group study[J].J Clin Oncol,2004,22(14):2873-2876.
[27]WOMER R B,WEST D C,KRAILO M D,et al.Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma:a report from the Children′s Oncology Group[J].J Clin Oncol,2012,30(33):4148-4154.
[28]DONALDSON S S.Ewing sarcoma:radiation dose and target volume[J].Pediatr Blood Cancer,2004,42(5):471-476.
[29]DUNST J,HOFFMANN C,AHRENS S,et al.Surgery versus radiotherapy in Ewing′s sarcoma with good prognosis.Analysis of the CESS-86 data[J].Strahlenther Onkol,1996,172(5):244-249.
[30]BOLEK T W,MARCUS R B Jr,MENDENHALL N P,et al.Local control and functional results after twice-daily radiotherapy for Ewing′s sarcoma of the extremities[J].Int J Radiat Oncol Biol Phys,1996,35(4):687-692.
[31]TALLEUR A C,NAVID F,SPUNT S L,et al.Limited margin radiation therapy for children and young adults with Ewing sarcoma achieves high rates of local tumor control[J].Int J Radiat Oncol Biol Phys,2016,96(1):119-126.
[32]ALBERGO J,GASTON C L L,PARRY M C,et al.Risk analysis factors for local recurrence in Ewing′s sarcoma:when should adjuvant radiotherapy be administered?[J].Bone Joint J,2018,100(2):247-255.
[33]GHAREDAGHI M,PEIVANDI M T,MAZLOOMI M,et al.Evaluation of clinical results and complications of structural allograft reconstruction after bone tumor surgery[J].Arch Bone Jt Surg,2016,4(3):236-242.
[34]OZAKI T,HILLMANN A,HOFFMANN C,et al.Significance of surgical margin on the prognosis of patients with Ewing′s sarcoma:a report from the Cooperative E-wing′s Sarcoma Study[J].Cancer,1996,78(4):892-900.
[35]SLUGA M,WINDHAGER R,LANG S,et al.The role of surgery and resection margins in the treatment of Ewing′s sarcoma[J].Clin Orthop Relat Res,2001(392):394-399.
[36]MIZOSHIRI N,SHIRAI T,TERAUCHI R,et al.Limb saving surgery for Ewing′s sarcoma of the distal tibia:a case report[J].BMC Cancer,2018,18(1):503.
[37]EL-NEGERY A,ELMOGHAZY N A,ABD-ELLATIFM S,et al.Vascularized fibular medialization for reconstruction of the tibial defects following tumour excision[J].Int Orthop,2017,41(10):2179-2187.
[38]RENARD A J,VETH R P,SCHREUDER H W,et al.Function and complications after ablative and limbsalvage therapy in lower extremity sarcoma of bone[J].JSurg Oncol,2000,73(4):198-205.
[39]CHOI Y,LIM D H,LEE S H,et al.Role of radiotherapy in the multimodal treatment of Ewing sarcoma family tumors[J].Cancer Res Treat,2015,47(4):904-912.
[40]MILLER B J,GAO Y,DUCHMAN K R.Does surgery or radiation provide the best overall survival in Ewing′s sarcoma?A review of the National Cancer Data Base[J].JSurg Oncol,2017,116(3):384-390.
[41]FOULON S,BRENNAN B,GASPAR N,et al.Can postoperative radiotherapy be omitted in localised standardrisk Ewing sarcoma?An observational study of the EuroEWING group[J].Eur J Cancer,2016,61:128-136.
[42]AHMED S K,ROBINSON S I,ARNDT C A S,et al.Pelvis Ewing sarcoma:local control and survival in the modern era[J].Pediatr Blood Cancer,2017,64(9):e26504.
[43]PURI A,GULIA A,CRASTO S,et al.Does radiotherapy after surgery affect outcomes in Ewing′s sarcoma of the pelvis?[J].Indian J Orthop,2018,52(1):73-76.
[44]BISWAS B,RASTOGI S,KHAN S A,et al.Outcomes and prognostic factors for Ewing-family tumors of the extremities[J].J Bone Joint Surg Am,2014,96(10):841-849.
[45]PAULINO A C,MAI W Y,TEH B S.Radiotherapy in metastatic Ewing sarcoma[J].Am J Clin Oncol,2013,36(3):283-286.
[46]ESIASHVILI N,GOODMAN M,MARCUS R B Jr.Changes in incidence and survival of Ewing sarcoma patients over the past 3decades:Surveillance epidemiology and end results data[J].J Pediatr Hematol Oncol,2008,30(6):425-430.
[47]RODRIGUEZ-GALINDO C,BILLUPS C A,KUN L E,et al.Survival after recurrence of Ewing tumors[J].Cancer,2002,94(2):561-569.
[48]BACCI G,FERRARI S,LONGHI A,et al.Role of surgery in local treatment of Ewing′s sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy[J].Oncol Rep,2004,11(1):111-120.
[49]ROBINSON S I,AHMED S K,OKUNO S H,et al.Clinical outcomes of adult patients with relapsed Ewing sarcoma:a 30-year single-institution experience[J].Am J Clin Oncol,2014,37(6):585-591.
[50]MCTIERNAN A,DRIVER D,MICHELAGNOLI M P,et al.High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing′s sarcoma family of tumours[J].Ann Oncol,2006,17(8):1301-1305.
[51]FERRARI S,DEL PREVER A B,PALMERINI E,et al.Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma[J].Pediatr Blood Cancer,2009,52(5):581-584.
[52]RACIBORSKA A,BILSKA K,DRABKO K,et al.Vincristine,irinotecan,and temozolomide in patients with relapsed and refractory Ewing sarcoma[J].Pediatr Blood Cancer,2013,60(10):1621-1625.
[53]YOON J H,KWON M M,PARK H J,et al.A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors[J].BMC Cancer,2014,14:622.
[54]LI S,YANG Q,WANG H,et al.Prognostic significance of serum lactate dehydrogenase levels in Ewing′s sarcoma:a meta-analysis[J].Mol Clin Oncol,2016,5(6):832-838.